Clinical trial protocols of new drugs for nonalcoholic steatohepatitis: A systematic review
10.3969/j.issn.1001-5256.2022.04.012
- VernacularTitle:非酒精性脂肪性肝炎新药临床试验方案的系统评价
- Author:
Yingshuo HUANG
1
;
Wei WEI
2
;
Xiaofei TONG
3
,
4
,
5
;
Yameng SUN
3
,
4
,
5
;
Jianxiong ZHANG
1
;
Ruihua DONG
1
;
Jidong JIA
3
,
4
,
5
;
Hong YOU
3
,
4
,
5
Author Information
1. Department of Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2. Department of Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
3. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
4. Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
5. National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Original Articles_Fatty Liver Diseases
- Keywords:
Nonalcoholic Steatohepatitis;
Clinical Trial;
Evaluation Studies
- From:
Journal of Clinical Hepatology
2022;38(4):798-804
- CountryChina
- Language:Chinese
-
Abstract:
Objective To describe the characteristics and registration status of clinical trials of new drugs for nonalcoholic steatohepatitis (NASH), and to provide a reference for the design and implementation of clinical trials of new drugs for NASH. Methods The U.S. Clinical Trials Database, China Clinical Trial Registry, and Center for Drug Evaluation, National Medical Products Administration, were searched for clinical trials of new drug registration and interventional studies with NASH as the indication published up to August 6, 2021, using NASH in English and Chinese characters as the keywords, and liver cirrhosis was excluded. Two researchers independently searched and screened the articles to extract relevant information. Results A total of 196 clinical trials of new drug registration or interventional studies for NASH were included, among which there were 174 trials registered abroad and 22 trials registered in China, and the number of registrations tended to increase year by year. The numbers of phase Ⅰ, phase Ⅰ/Ⅱ(including Ⅰb/Ⅱa), phase Ⅱ, phase Ⅱ/Ⅲ, and phase Ⅲ clinical trials were 45(23.0%), 8(4.1%), 112(57.1%), 4(2.0%), and 19(9.7%), respectively. The main drug types included farnesoid X receptors, fibroblast growth factors, peroxisome proliferator-activated receptor agonists, and glucagon-like peptide-1, with numbers of 16(8.16%), 14(7.14%), 11(5.61%), and 13(6.63%), respectively. The clinical trials of innovative drugs for NASH initiated by the sponsors in European and American regions accounted for the highest proportion, and there was a gradual increase in the number of clinical trials of innovative drugs in China in recent years, with a similar distribution of single-center and multicenter clinical trials. As for the trials with NASH patients as subjects, the numbers of trials with pathology, imaging, and clinical diagnosis as the main inclusion criteria were 125, 66, and 42, respectively. Phase Ⅰ clinical trials used safety, tolerability, and pharmacokinetic parameters as the main assessment indices, while phase Ⅱ and phase Ⅲ clinical trials often used safety and efficacy as the main assessment indices. The number of clinical trials for the registration of innovative drugs for NASH was relatively low but kept increasing in China, and there were fewer clinical trials of innovative traditional Chinese medicine drugs compared with innovative chemical drugs. Conclusion There is a significant increase in the registration of international clinical trials of innovative drugs for NASH, and most of these trials are in the early phases, with large differences in inclusion criteria and assessment indices, a lack of unified evaluation indices, and relatively few trials with new designs. There are fewer clinical trials of innovative drugs for NASH in China than in European and American countries, and the number of such trials is gradually increasing in China.
